LONDON (Reuters) -GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit growth, lifting the British company's shares by nearly 7% to ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

GSK Plc’s experimental mRNA flu vaccine showed a positive immune response against two key types of flu viruses in a mid-stage trial, keeping the drugmaker in the race to bring the technology to ...

Drugs giant GSK saw its shares drift lower despite announcing progress on two key products yesterday. The FTSE 100 firm said its experimental chronic hepatitis B drug bepirovirsen, branded Hibsago, ...

GSK plc GSK announced that it has entered into a definitive agreement to acquire California-based biotech RAPT Therapeutics RAPT for an estimated aggregate equity value of $2.2 billion. The impending ...